Page 40 - Priority Review News Today

UCB announces approval of RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in JapanJapanese Ministry of Health, Labour and Welfare (MHLW) approves two UCB treatments, RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan), f...

26.09.2023 - If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat Of the approximately 21,000 children under the age ...

If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat ...

Results from EoE KIDS showed 68% of patients on a higher dose of dupilumab and 58% of patients on a lower dose achieved significant histological disease remission.

The FDA has accepted for Priority Review the sBLA for dupilumab for the treatment of eosinophilic esophagitis in children 1 to 11 years of age.

Prestige Biologics, a contract development and manufacturing organization (CDMO), announced it has signed a non-binding MOU with Aurigene…

UCB announces approval of RYSTIGGO[®] and ZILBRYSQ[®] for the treatment of adult patients with generalized myasthenia gravis in Japan Japanese Ministry...

/PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Fast Track Designation...

/PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for...

 Product sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited...